# Adolescent Cannabis Quit Attempts Lag Behind Tobacco > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/adolescent-cannabis-quit-attempts-2026/ > **Published:** 2026-09-13T11:25:32-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:02-04:00 > **Clinical Summary:** Adolescent cannabis quit attempts were less common than vaping or cigarette quit attempts in a large California student survey. --- CED Clinical Relevance #75 High Public Health Relevance A newly published peer-reviewed analysis directly compares past-year quit attempts for cannabis, nicotine vaping, and cigarettes within the same large California student survey. Search-demand and engagement components are editorially inferred because current GSC data were unavailable. Clinical Insight | CED Clinic A peer-reviewed analysis compared past-year quit attempts among 25,930 California adolescents reporting past-month cannabis, nicotine-vape, or cigarette use. Cannabis users reported fewer quit attempts, 38.7%, than vaping users, 52.9%, or cigarette users, 47.7%. Perceived harm predicted quit attempts across products, and cannabis was perceived as least harmful. The cross-sectional survey cannot establish why adolescents did or did not try to quit, whether attempts produced sustained change, or whether changing risk perception alone would alter behavior. Clinically, the findings support asking directly about motivation, prior attempts, co-use, functioning, and the kind of support an adolescent would accept. Adolescent HealthCannabis UseQuit AttemptsRisk PerceptionPublic Health AudiencePatients, caregivers, clinicians, and cannabis-science readers interested in adolescent cannabis use and prevention Primary Topicadolescent cannabis quit attempts compared with nicotine vaping and cigarette quit attempts Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42731276/) Among 25,930 California adolescents reporting past-month cannabis, nicotine-vape, or cigarette use, 38.7% of cannabis users reported a past-year quit attempt. The comparable rates were 52.9% for vaping and 47.7% for cigarettes. The survey analysis links quit attempts with perceived harm but does not establish why individual adolescents did or did not try to quit. What This Study Teaches Us The study provides a direct, same-survey comparison of quitting behavior across three products. Cannabis users reported fewer quit attempts, and cannabis was perceived as the least harmful product. Perceived harm predicted quit attempts across all three product groups. Why This Matters Prevention messages often focus on whether adolescents use a substance. Quit attempts add another clinically useful question because they can reveal motivation, perceived risk, and opportunities for confidential support among young people who already use cannabis or nicotine products. Study SnapshotStudy TypeCross-sectional analysis of the 2019 to 2020 California Student Tobacco SurveySurvey Population162,675 middle and high school studentsAnalytic Sample25,930 adolescents reporting past-month cannabis, nicotine-vape, or cigarette usePrimary MeasureSelf-reported past-year quit attempt for each product usedCannabis Quit Attempts38.7%Nicotine-Vape Quit Attempts52.9%Cigarette Quit Attempts47.7%Risk PerceptionPerceived harm predicted quit attempts across cannabis, vaping, and cigarettesProduct ComparisonCannabis was perceived as the least harmful of the three productsAge FindingOlder age predicted fewer cannabis quit attempts, but not fewer vaping or cigarette quit attemptsGender FindingThe abstract reports no gender differences in quit-attempt rates for any of the three productsPrimary BoundaryThe analysis identifies associations and cannot establish the reason for individual quit behaviorPublishedSeptember 8, 2026PMID42731276DOI10.1016/j.drugalcdep.2026.113356 Clinical Bottom Line California adolescents who used cannabis reported fewer past-year quit attempts than peers who used nicotine vapes or cigarettes. Perceived harm was associated with quit attempts, but the study does not show that changing risk perception alone will cause cessation. Quit Attempts Differed by Product Within the 25,930 adolescents reporting past-month use of at least one studied product, 38.7% of cannabis users reported a past-year quit attempt. The rate was 52.9% among nicotine-vape users and 47.7% among cigarette users. The cannabis difference was statistically significant compared with both tobacco-product groups. The abstract reports no statistically significant difference between vaping and cigarette quit-attempt rates. Perceived Harm Traveled With Motivation Perceived harm consistently predicted quit attempts across cannabis, nicotine vaping, and cigarettes. Cannabis was also perceived as the least harmful of the three products in this survey population. That association is clinically relevant, but it is not proof that a risk message will produce a quit attempt. The authors state that perceptions and social norms may partly contribute and should be considered in prevention work. Age and Social Context May Matter Older age predicted fewer cannabis quit attempts, while the abstract did not report the same age pattern for vaping or cigarettes. Race and ethnicity patterns varied by product, and parental education was negatively associated with quit attempts only for cannabis. These findings argue against treating all adolescent substance use as one behavior. They do not establish a biological or social mechanism, and the abstract does not provide enough detail for individualized subgroup conclusions. What the Abstract Cannot Resolve The source describes a survey analysis rather than a treatment or prevention trial. It does not show whether a quit attempt led to abstinence, reduced use, relapse, treatment engagement, or a change in cannabis use disorder symptoms. Full text was not openly available for this review. Unreported questionnaire details, response patterns, model specifications, missing-data handling, and additional subgroup analyses were therefore not used in the article. How Strong Is This Evidence? The analysis uses a large statewide student survey and applies the same quit-attempt concept to cannabis, nicotine vaping, and cigarettes. This makes the product comparison more interpretable than comparisons assembled from separate surveys using different questions. Where This Paper Deserves Skepticism The evidence comes from self-reported survey data collected in 2019 to 2020. The abstract presents associations among product use, perceived harm, and quit attempts, but it does not establish causal direction or report whether attempts resulted in sustained cessation. What This Paper Does Not Show The study does not show that cannabis is safer or more harmful than nicotine products, that lower perceived harm caused fewer quit attempts, that a particular prevention message will work, or that every adolescent cannabis user needs the same intervention. How This Fits With the Broader Clinical Conversation Adolescent counseling can miss a useful middle ground when it asks only whether cannabis is used. Asking whether a young person has wanted to cut down, tried to stop, or noticed problems can open a more specific discussion about motivation and support. Risk communication should remain accurate and proportionate. Exaggerated claims can erode trust, while silence can leave adolescents to interpret lower perceived harm as absence of risk. The study supports attention to perception without prescribing one message or program. Dr. Caplan’s Take *The clinically useful signal is not that adolescents lack concern. It is that quit behavior differs across products, and cannabis may occupy a distinct place in how young people weigh risk, norms, and reasons to change.* *I would ask about goals before delivering a lecture. Frequency, context, co-use, impairment, school function, mood, sleep, driving, and prior quit experiences can turn a broad prevention message into a safer and more respectful conversation.* What a Careful Reader Should Take Away Use the study to improve questions about motivation and perceived risk. Do not treat a cross-sectional association as proof of why adolescents use cannabis or how best to help them stop. Evidence Interpretation Guide Table of Contents - [How to Interpret This Adolescent Cannabis Quit Attempts Compared With Nicotine Vaping And Cigarette Quit Attempts Evidence Without Overstating It](#How_to_Interpret_This_Adolescent_Cannabis_Quit_Attempts_Compared_With_Nicotine_Vaping_And_Cigarette_Quit_Attempts_Evidence_Without_Overstating_It)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [Eight Ways to Read the Adolescent Quit-Attempt Gap](#Eight_Ways_to_Read_the_Adolescent_Quit-Attempt_Gap)[A Quit Attempt Is a Health Signal, Not a Moral Verdict](#A_Quit_Attempt_Is_a_Health_Signal_Not_a_Moral_Verdict) - [Screen for Motivation Alongside Frequency and Harm](#Screen_for_Motivation_Alongside_Frequency_and_Harm) - [A Large Sample Strengthens Precision, Not Causal Inference](#A_Large_Sample_Strengthens_Precision_Not_Causal_Inference) - [Lower Perceived Harm Should Not Be Read as No Harm](#Lower_Perceived_Harm_Should_Not_Be_Read_as_No_Harm) - [Curiosity Can Preserve Communication](#Curiosity_Can_Preserve_Communication) - [One Message May Not Fit Three Products](#One_Message_May_Not_Fit_Three_Products) - [Subgroup Patterns Need Context Before Action](#Subgroup_Patterns_Need_Context_Before_Action) - [Follow Quit Attempts Through Outcomes](#Follow_Quit_Attempts_Through_Outcomes) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Adolescent Cannabis Quit Attempts Compared With Nicotine Vaping And Cigarette Quit Attempts Evidence Without Overstating It A useful evidence report should let the signal breathe without inflating it. The right question is not whether the paper is positive or negative, but what kind of decision it can responsibly support. ### A Four-Step Reading Frame **Evidence type**Start by identifying whether the paper is a randomized trial, review, meta-analysis, observational study, or protocol. **Population**Ask whether the studied population matches the patient or clinical scenario involving adolescent cannabis use and prevention. **Outcome meaning**Look at what actually changed, how it was measured, and whether the change would matter in daily life. **Safety and uncertainty**Read limitations and adverse effects as part of the result, not as a footnote. The Research Question What does the current evidence suggest about adolescent cannabis quit attempts compared with nicotine vaping and cigarette quit attempts? The Patient Question Does this mean I should use cannabinoids for adolescent cannabis use and prevention? The Bottom Line The evidence can inform a careful conversation, but it does not replace individualized clinical care. CED Perspective Lens ## Eight Ways to Read the Adolescent Quit-Attempt Gap Clinical, family, prevention, methods, safety, equity, and research perspectives Lens OverviewEach lens separates the observed product differences from untested explanations and focuses on respectful, specific opportunities for prevention and care. #### A Quit Attempt Is a Health Signal, Not a Moral Verdict The survey found that adolescents who used cannabis were less likely to report a past-year quit attempt than peers who vaped nicotine or smoked cigarettes. That difference does not reveal what any one teenager wants, whether use is occasional or frequent, or whether a prior attempt felt successful. A confidential conversation can begin with goals: stopping, cutting back, avoiding use before school or driving, or understanding effects on mood and sleep. The study does not test a counseling method, but it supports asking about motivation directly instead of assuming that cannabis users are either unconcerned or ready to quit. Lens takeawayAsk what change would feel useful and safe before deciding what support fits. #### Screen for Motivation Alongside Frequency and Harm The same-survey comparison gives clinicians a reason to ask about quit attempts across cannabis, vaping, and cigarettes rather than grouping all products together. Past attempts can reveal motivation, triggers, withdrawal concerns, and places where practical support has been missing. Assessment should also include frequency, potency when known, co-use, impaired driving, school function, mood, anxiety, sleep, and symptoms consistent with cannabis use disorder. The abstract does not validate a screening instrument or intervention, so the finding should shape inquiry, not create a new diagnostic shortcut. Lens takeawayTreat quit history as one part of a broader, confidential adolescent assessment. #### A Large Sample Strengthens Precision, Not Causal Inference The researchers analyzed 25,930 past-month users drawn from 162,675 California middle and high school students. Cannabis, vaping, and cigarette quit attempts were assessed within the same survey, addressing a comparability problem in earlier studies that used different samples or measures. The design remains cross-sectional and self-reported. It can show that perceived harm and quit attempts were associated, but not which came first or whether another factor shaped both. The unavailable full text also prevents independent review here of questionnaire wording, missing data, and complete model specifications. Lens takeawayUse the product comparison confidently, while keeping causal explanations provisional. #### Lower Perceived Harm Should Not Be Read as No Harm Cannabis was perceived as the least harmful of the three products, and perceived harm predicted quit attempts across all products. The study does not measure comparative toxicity, so the perception result cannot rank the actual health burden of cannabis, vaping, and cigarettes. Safety discussions should be specific to developmental stage and behavior. Important topics can include intoxication, driving, high-potency exposure, anxiety or psychotic symptoms, school impairment, medication interactions, and progression toward problematic use. Accurate language matters because exaggeration can undermine the trust needed for disclosure. Lens takeawayExplain concrete risks without converting a perception survey into a toxicity ranking. #### Curiosity Can Preserve Communication Parents and caregivers may interpret a lack of quit attempts as defiance or denial. The study cannot identify an individual adolescent’s reasons, and its findings leave room for perceived harm, social norms, product availability, dependence, stress, and other factors to differ from person to person. Open questions are more likely to produce useful information: What does cannabis do for you? What problems have you noticed? Have you tried to change? What made that easier or harder? Safety boundaries remain important, especially around driving and younger siblings, but they work best alongside listening and access to confidential clinical support. Lens takeawayCombine clear safety expectations with questions that make honest disclosure possible. #### One Message May Not Fit Three Products Quit-attempt rates and demographic patterns differed across cannabis, nicotine vaping, and cigarettes. That suggests adolescents may interpret each product through a different mix of risk beliefs and social norms, even when they use more than one product. Prevention programs can acknowledge those differences while avoiding unsupported promises. This paper does not test a campaign, school program, or clinical intervention. Its contribution is to identify perceptions and quitting behavior as targets for future study, with enough product specificity to avoid treating every form of substance use as interchangeable. Lens takeawayDesign prevention around product-specific beliefs, then test whether the message changes behavior. #### Subgroup Patterns Need Context Before Action The abstract reports that race and ethnicity patterns varied across products, while parental education was negatively associated with quit attempts only for cannabis. Those findings may reflect differences in norms, access, exposure, enforcement, stress, or survey context, but the abstract does not establish an explanation. Programs should resist turning demographic associations into stereotypes. Community input, culturally responsive communication, confidential care, and attention to unequal disciplinary consequences can help prevention efforts support adolescents rather than intensify surveillance. Full subgroup estimates and methods would be needed before drawing narrower conclusions. Lens takeawayUse demographic findings to ask better contextual questions, not to label young people. #### Follow Quit Attempts Through Outcomes The next step is longitudinal research that distinguishes desire to quit, planning, attempts, reduced use, sustained abstinence, relapse, and treatment engagement. Repeated measures could help clarify whether perceived harm predicts later change or whether quitting experiences reshape perceived harm. Intervention studies should compare accurate product-specific education, motivational approaches, family support, digital tools, and clinical referral pathways. Outcomes should include cannabis and nicotine use, functioning, mental health, driving risk, and unintended effects such as stigma or reduced disclosure. Co-use deserves explicit analysis because many adolescents use more than one product. Lens takeawayTrack what happens after motivation appears, not only whether an attempt was reported. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Adolescent+Cannabis+Quit+Attempts+Lag+Behind+Tobacco&url=https%3A%2F%2Fcedclinic.com%2Fadolescent-cannabis-quit-attempts-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fadolescent-cannabis-quit-attempts-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Adolescent+Cannabis+Quit+Attempts+Lag+Behind+Tobacco%20https%3A%2F%2Fcedclinic.com%2Fadolescent-cannabis-quit-attempts-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Adolescents are less likely to attempt to quit cannabis than tobacco: The potential role of lower risk perception.](https://pubmed.ncbi.nlm.nih.gov/42731276/) Related Reading at CED ClinicContinue exploring the evidence[California Study Tracks Adolescent CUD After Cannabis Legalization](https://cedclinic.com/california-adolescent-cud-legalization-2026/) A population-based California study provides recent context on diagnosed cannabis use disorder trends after legalization. [Read the California context](https://cedclinic.com/california-adolescent-cud-legalization-2026/)[Solitary Cannabis Use in Teens: What a Norwegian National Study Found](https://cedclinic.com/solitary-cannabis-use-teens-norway/) National survey evidence explores how solitary use can identify a different pattern of adolescent cannabis risk. [Review the teen-use study](https://cedclinic.com/solitary-cannabis-use-teens-norway/)[Social Media Apps and Youth Cannabis Use: What the ABCD Study Found](https://cedclinic.com/app-specific-social-media-use-adolescent-cannabis/) Longitudinal youth data place cannabis behavior within a broader prevention and media environment. [Explore youth prevention context](https://cedclinic.com/app-specific-social-media-use-adolescent-cannabis/) ## Frequently Asked Questions What survey did the researchers analyze? They analyzed the 2019 to 2020 California Student Tobacco Survey of 162,675 middle and high school students. How many adolescents were included in the product-use analysis? The analytic sample included 25,930 adolescents reporting past-month cannabis, nicotine-vape, or cigarette use. How common were cannabis quit attempts? Among adolescents who used cannabis, 38.7% reported a past-year quit attempt. How did that compare with nicotine products? Past-year quit attempts were reported by 52.9% of nicotine-vape users and 47.7% of cigarette users. Did vaping and cigarette quit-attempt rates differ? The abstract reports no statistically significant difference between the vaping and cigarette rates. What role did perceived harm play? Higher perceived harm predicted quit attempts across cannabis, nicotine vaping, and cigarettes, and cannabis was perceived as the least harmful product. Does the study prove that lower risk perception caused fewer cannabis quit attempts? No. The survey analysis found an association, but it cannot establish causal direction or explain every adolescent's motivation. Did the study measure successful quitting? The abstract reports past-year quit attempts. It does not report sustained abstinence, relapse, or treatment outcomes. Was the full article available for this review? No. The peer-reviewed PubMed abstract and identifier record were reviewed, so study-specific claims are limited to information reported there. What is the practical takeaway for families and clinicians? Ask adolescents directly and without judgment about goals, prior quit attempts, perceived risks, co-use, functioning, and what support they would accept. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).